News Feed Item

Professor Raymond Schinazi Joins Board of reViral as Non-executive Director

LONDON, April 15, 2014 /PRNewswire/ --

reViral, an antiviral drug discovery and development company, focused on diseases caused by the respiratory syncytial virus (RSV), today announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014.

Professor Schinazi has had a long and prestigious career in the industry having founded several successful biotechnology companies including Pharmasset, where he chaired the Board and directed the scientific research that lead to the discovery of Solvadi, a curative drug for hepatitis C virus infections, as well as previously commercialising inventions that have revenues of over $2 billion per year.

Ken Powell, Chairman and Founder of reViral, commented on the appointment:  "We are very pleased to have attracted someone of Ray's experience and prestige to reViral.  A world leader in nucleoside chemistry and biology, Ray's discoveries have made a tangible impact on the quality of life and welfare of society. His remarkable accomplishments and wealth of experience will be integral to reViral as the company grows to become a leader in the antiviral space."  

Professor Schinazi, newly appointed Non-Executive Director of reViral said:  "reViral is at the forefront of RSV treatments, developing novel first-in-class compounds that have the potential to revitalise and transform the market.  I look forward to working with the proven management team and am excited by the Company's highly promising programme and pipeline, as it expands into areas of high unmet need." 

Khatereh Ahmadi, Chief Executive Officer and Founder of reViral added:  "The lack of treatment options for RSV and limited competition offers a significant market for innovative therapies like ours. Professor Schinazi's track record will be invaluable to reViral as we look to bring our novel treatments for RSV to the market place, selecting a preclinical candidate this year and entering IND enabling studies in 2015." 

reViral has developed a novel series of antiviral inhibitors targeting RSV fusion - including its lead compound (RV521) - which is highly potent and orally bioavailable with strong drug like characteristics.  RSV is the most important respiratory pathogen with 64 million infections and as many as 200,000 deaths worldwide annually in children under 5 years alone. There are currently no RSV vaccines available and there is an urgent need for improved drugs for this indication.

Professor Schinazi holds a Bachelor of Science, a Ph.D. and received an Honorary Doctor of Science degree for his research accomplishments in the field of HIV and biotechnology from the University of Bath, England, and completed postdoctoral training in Pharmacology at Yale University and in Virology/Immunology from Emory University.


About Professor Schinazi 

Professor Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR).  Dr. Schinazi received his BSc (1972) and PhD (1976) in chemistry from the University of Bath, England.  He has authored over 500 peer-reviewed papers and 7 books and holds 92 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 12 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies including Pharmasset, Inc. (VRUS; acquired by Gilead in 2012 for 11.4 B). More than 94% of HIV-infected individuals in the US on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 3 million lives worldwide.  His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous awards including the 2006 Distinguished Scientist Award from the Hepatitis B Foundation, the Friends of the National Library of Medicine 2013 Distinguished Medical Science Award, and the SCRIP "100 Leaders" Award in 2014. He was also chosen in 2011 as one of Emory University's "175 History Makers." He currently serves as a Governing Trustee for the Foundation for AIDS Research (amfAR). He was inducted into the Technology Hall of Fame of Georgia in March 2012, received the Intellectual Property Legends Award in October 2012, and was inducted into the National Academy of Inventors as a Charter Fellow in January 2013. Dr. Schinazi is internationally recognized as one of the most influential persons in the life science sector.

About reViral  

ReViral is an antiviral drug discovery and development company, focused on novel antiviral treatments for diseases caused by the respiratory syncytial virus (RSV).

Founded in 2011, reViral has an experienced R&D leadership team with a successful track record in antiviral drug discovery and development.  The company has developed a novel antiviral program targeting RSV fusion with highly potent, orally bioavailable inhibitors with strong drug like characteristics and good pharmacokinetic properties offering versatility in route of administration. In 2012 reViral won a significant Seeding Drug Discovery Initiative Award from the Wellcome Trust to develop its RSV fusion inhibitors to completion of IND filing. The company also has an RSV replication program at an earlier stage of development and plans to expand its pipeline in other antivirals for diseases with a high unmet need.

About Human Respiratory Syncytial Virus (RSV) 

Human Respiratory Syncytial Virus (RSV) is the most important respiratory pathogen, responsible for one-fifth of all lower respiratory tract infections worldwide. Historically it has been considered to be solely an infection of children, however, with the ever-increasing awareness of diseases of the elderly and immunocompromised patient populations this perception is changing.

RSV infection is responsible for more infant hospitalizations than other viral infections such as influenza. Susceptible populations are premature infants, children, transplant patients, the elderly and people of all ages with heart failure and lung disease. In addition, severe infection in infancy is linked to the later development of asthma. In the elderly in the US it was shown that RSV infection caused 177,500 hospital admissions and 14,000 deaths over a period of 4 years.  Hospitalization costs alone were estimated at more than $1 billion.


reViral: Khatereh Ahmadi, CEO
Tel: +44(0)78-0158-4398, Email: [email protected]

Hume Brophy: Mary Clark, Hollie Vile, Supriya Mathur
Tel: +44(0)20-3440-5654, Email: [email protected]

SOURCE reViral

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Successful transition from traditional IT to cloud computing requires three key ingredients: an IT architecture that allows companies to extend their internal best practices to the cloud, a cost point that allows economies of scale, and automated processes that manage risk exposure and maintain regulatory compliance with industry regulations (FFIEC, PCI-DSS, HIPAA, FISMA). The unique combination of VMware, the IBM Cloud, and Cloud Raxak, a 2016 Gartner Cool Vendor in IT Automation, provides a co...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
SYS-CON Events announced today that Niagara Networks will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Niagara Networks offers the highest port-density systems, and the most complete Next-Generation Network Visibility systems including Network Packet Brokers, Bypass Switches, and Network TAPs.
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
SYS-CON Events announced today that StarNet Communications will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. StarNet Communications’ FastX is the industry first cloud-based remote X Windows emulator. Using standard Web browsers (FireFox, Chrome, Safari, etc.) users from around the world gain highly secure access to applications and data hosted on Linux-based servers in a central data center. ...
SYS-CON Events announced today that Cemware will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Use MATLAB functions by just visiting website mathfreeon.com. MATLAB compatible, freely usable, online platform services. As of October 2016, 80,000 users from 180 countries are enjoying our platform service.
Virgil consists of an open-source encryption library, which implements Cryptographic Message Syntax (CMS) and Elliptic Curve Integrated Encryption Scheme (ECIES) (including RSA schema), a Key Management API, and a cloud-based Key Management Service (Virgil Keys). The Virgil Keys Service consists of a public key service and a private key escrow service. 

SYS-CON Events announced today that eCube Systems, the leading provider of modern development tools and best practices for Continuous Integration on OpenVMS, will exhibit at SYS-CON's @DevOpsSummit at Cloud Expo New York, which will take place on June 7-9, 2016, at the Javits Center in New York City, NY. eCube Systems offers a family of middleware products and development tools that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...